Download PDF
Int J Angiol 2012; 21(02): 095-098
DOI: 10.1055/s-0032-1315626
Case Report

Recurrent Unprovoked Venous Thromboembolism in a Young Female Patient with High Levels of Homocysteine

Ashish Anil Sule
1   Department of General Medicine, Subspecialty of Vascular Medicine and Hypertension, Tan Tock Seng Hospital, Singapore
,
Tay Jam Chin
1   Department of General Medicine, Subspecialty of Vascular Medicine and Hypertension, Tan Tock Seng Hospital, Singapore
,
Lee Hwei Khien
2   Department of Pharmacy, Tan Tock Seng Hospital, Singapore
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Hyperhomocysteinemia is a rare condition which predisposes to atherothrombosis. Recurrent venous thromboembolism (VTE) with hyperhomocysteinemia is known but extremely uncommon. Homocysteine levels of more than 22 umol/L can predispose to VTE in a middle-aged women. We describe a case of a middle-aged woman, community ambulant with recurrent VTE with intermediately high homocysteine levels. She had no other risk factors for recurrent venous thrombosis. In our article, we also discuss hyperhomocysteinemia and its link to VTE.

Keywords

antifactor Xa - cardiovascular risk factors - deep vein thrombosis - factor V Leiden - hypertension - thrombophilia


Publication History

Publication Date:
28 May 2012 (online)

© 2012. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Varga EA, Sturm AC, Misita CP, Moll S. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation 2005; 111 (19) e289-e293
    CrossrefPubMedGoogle Scholar
  • 2 Lonn E, Yusuf S, Arnold MJ. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. et al Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354 (15) 1567-1577
    CrossrefPubMedGoogle Scholar
  • 3 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274 (13) 1049-1057
    CrossrefPubMedGoogle Scholar
  • 4 Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-298
    CrossrefPubMedGoogle Scholar
  • 5 Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338 (15) 1042-1050
    CrossrefPubMedGoogle Scholar
  • 6 Mudd SH, Levy HL, Skovby F, Disorders of transsulfuration In: Scriver CR, Beaudet AL, Sly WS, Valle D. eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill; 1995: 1279-1327
    Google Scholar
  • 7 Carey MC, Donovan DE, FitzGerald O, McAuley FD. Homocystinuria. I. A clinical and pathological study of nine subjects in six families. Am J Med 1968; 45 (01) 7-25
    PubMedGoogle Scholar
  • 8 Malinow MR, Kang SS, Taylor LM. et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79 (06) 1180-1188
    CrossrefPubMedGoogle Scholar
  • 9 Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21 (04) 572-576
    CrossrefPubMedGoogle Scholar
  • 10 Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson O, Upson B. Homocyst(e)ine in daily practice: levels in coronary heart disease. Coron Artery Dis 1990; 1: 4-12
    CrossrefPubMedGoogle Scholar
  • 11 Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 1972; 46 (02) 905-912
    CrossrefPubMedGoogle Scholar
  • 12 Erbe RW, Inborn errors of folate metabolism In: Blakely RL, Whitehead VM. eds. Folate and Pterins: Nutritional, Pharmacological, and Physiological Aspects. New York: Marcel Dekker; 1986: 413-425
    Google Scholar
  • 13 D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 14 Wilcken DE, Gupta VJ. Sulphr containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979; 9 (04) 301-307
    CrossrefPubMedGoogle Scholar
  • 15 Chauveau P, Chadefaux B, Coudé M. et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41: S72-S77
    PubMedGoogle Scholar
  • 16 Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114 (05) 473-501
    PubMedGoogle Scholar
  • 17 Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27 (03) 517-527
    CrossrefPubMedGoogle Scholar
  • 18 Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991; 51 (03) 828-835
    PubMedGoogle Scholar
  • 19 Ueland PM, Refsum H, Brattstrom L, Plasma homocysteine and cardiovascular disease In: Francis Jr RB. ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York: Marcel Dekker; 1992: 183-236
    Google Scholar
  • 20 Ubbink JB, van der Merwe A, Delport R. , et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98 (01) 177-184
    CrossrefPubMedGoogle Scholar
  • 21 McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56 (01) 111-128
    PubMedGoogle Scholar
  • 22 Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677—> Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77 (05) 818-821
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Ma J, Stampfer MJ, Hennekens CH. , et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94 (10) 2410-2416
    CrossrefPubMedGoogle Scholar
  • 24 van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95 (01) 21-23
    CrossrefPubMedGoogle Scholar
  • 25 den Heijer M, Koster T, Blom HJ. , et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334 (12) 759-762
    CrossrefPubMedGoogle Scholar